Open Access
Anti-EGFR monoclonal antibody in cancer treatment: in vitro and in vivo evidence
Anna Elisa Quatrale1,Daniela Petriella1,Letizia Porcelli1,Stefania Tommasi1,Nicola Silvestris1,Giuseppe Colucci1,Angelo Angelo1,Amalia Azzariti1
Clinical Experimental Oncology Laboratory, National Cancer Institute Giovanni Paolo II, Via Hahnemann 10, 70126 Bari, Italy
DOI: 10.2741/3834 Volume 16 Issue 5, pp.1973-1985
Published: 01 January 2011

The complexity of EGFR signaling network suggests that the receptor could be promising targets for new personalised therapy. In clinical practice two strategies targeting the receptor are available; they utilise monoclonal antibodies, directed towards the extracellular domain of EGFR, and small molecule tyrosine kinase inhibitors, which bind the catalytic kinase domain of the receptor. In this review, we summarise currently known pre-clinical data on the antitumor effects of monoclonal antibodies, which bind to EGFR in its inactive configuration, competing for ligand binding and thereby blocking ligand-induced EGFR tyrosine kinase activation. As a consequence of treatment, key EGFR-dependent intracellular signals in cancer cells are affected. Data explaining the mechanisms of action of anti-EGFR monoclonal antibodies, currently used in clinical setting and under development for the treatment of solid tumors, are revised with the aim to provide an overview of the most important preclinical studies showing the impact of this class of EGFR targeted agents on tumor biology.

Share and Cite
Anna Elisa Quatrale, Daniela Petriella, Letizia Porcelli, Stefania Tommasi, Nicola Silvestris, Giuseppe Colucci, Angelo Angelo, Amalia Azzariti. Anti-EGFR monoclonal antibody in cancer treatment: in vitro and in vivo evidence. Frontiers in Bioscience-Landmark. 2011. 16(5); 1973-1985.